Lifting weights may unlock key to better insulin sensitivity
NCT ID NCT04158375
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study from the Mayo Clinic looked at how resistance exercise (like weight lifting) improves insulin sensitivity and muscle health in people with insulin resistance and obesity. 58 participants aged 50-75 completed a 3-month exercise program. Researchers measured changes in muscle strength, insulin sensitivity, and body composition to understand the underlying molecular benefits.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Resistance exercise training
- What this could lead to
- If successful, this could help explain why resistance exercise improves insulin sensitivity and muscle health, potentially guiding future exercise recommendations.
- What could go wrong
- This is a small, completed observational study (58 participants) that looks at biological mechanisms, not a treatment trial. Results may not apply to everyone and do not test a new drug or therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
58 people
The number who actually took part.
- Started
-
Sep 2020
- Finished
-
Sep 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria * age 50-75yrs * BMI 30-38kg/m2 * hip to waist ratio of \>0.85 in women and 1.0 in men * fasting glucose ≥100-140mg/dl Lean Group * age 50-75 years * hip to waist ratio of \<0.76 in women and 0.90 in men * fasting glucose of \<100mg/dl. Exclusion criteria for the study are as follows: * Coronary artery disease or heart failure. * Participation in a structured exercise program \>2 days per week * A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples: * Inpatient psychiatric treatment in the past 6 months * Presence of a known adrenal disorder * Abnormal liver function test results (Transaminase \>2 times the upper limit of normal); testing required for subjects taking medications known to affect liver function or with diseases known to affect liver function * Abnormal renal function test results (calculated GFR \<60 mL/min/1.73m2); testing required for subjects with diabetes duration of greater than 5 years post onset of puberty * Active gastroparesis * If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study * Uncontrolled thyroid disease (TSH undetectable or \>10 mlU/L); testing required within three months prior to admission for subjects with a goiter, positive antibodies, or who are on thyroid hormone replacement, and within one year otherwise * Abuse of alcohol or recreational drugs * Infectious process not anticipated to resolve prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis). * Uncontrolled arterial hypertension (Resting diastolic blood pressure \>90 mmHg and/or systolic blood pressure \>160 mmHg) at the time of screening. * Oral steroids * A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol * Restrictions on Use of Other Drugs or Treatments: * Medications that may impact study end points such as mitochondrial biology eg. beta blockers * Anti-hyperglycemic drugs including metformin * Any other medication that the investigator believes is a contraindication to the subject's participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Insulin resistance are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A multicenter, randomized, Active-Controlled, Open-Label phase IIb study evaluating safety and tolerability of switching to zovaglutide injection after titration to 2.4 mg semaglutide injection (Wegovy®) in adults with obesity (HORIZON-SWITCH-SZ)
- Gonadotropin-releasing hormone agonist (GnRHa) plus letrozole in obese progestin-insensitive early-stage endometrial cancer patients with conservative treatment
- Safety and feasibility of the ENDOPLY system in humans: a pilot study
- Dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like Peptide-1 (GLP-1) receptor agonist in women with obesity for frozen embryo transfer (FET): pragmatic, multicenter, randomized controlled trial
- Effects of very low calorie ketogenic diet on microbiota, adipose tissue and immunitary regulation: pilot study on patients with metabolic syndrome
- Susceptibility to infectious diseases in obesity: an endocrine, translational, sociological evaluation